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Abstract
Background: Pneumonia and respiratory failure are common problems in the intensive care unit (ICU) setting,
often occurring together. The relative prevalence of pneumonia types (community acquired, hospital acquired,
ventilator associated) and causative pathogens is not well described in patients with respiratory failure.
Methods: This was a prospective observational cohort study conducted in the medical ICU (34 beds) of Barnes-
Jewish Hospital, an academic referral center of 1,300 beds from January 2016–December 2016. All patients
who were prospectively adjudicated to have respiratory failure and pneumonia (RFP) regardless of pneumo-
nia type were classified into one of four microbiologic categories: pathogen negative, antibiotic-susceptible
pathogen (according to ceftriaxone susceptibility), antibiotic-resistant pathogen, and viruses. The primary
outcomes assessed were the hospital mortality rate and inappropriate initial antibiotic therapy (IIAT) for non-
viral pathogens.
Results: Among 364 consecutive patients with RFP, 63 (17.3%) had organisms that were antibiotic susceptible,
104 (28.6%) had antibiotic-resistant organisms, 118 (32.4%) were pathogen negative, and 79 (21.7%) had viral
infections. For these categories, IIAT occurred in 3.2%, 21.2%, 0.8%, and 0, respectively (p< 0.001).
Vasopressor-requiring shock was present in 61.9%, 72.1%, 68.6%, and 67.1%, respectively (p= 0.585), and the
hospital mortality rates were 27.0%, 48.1%, 31.4%, and 36.7%, respectively (p = 0.020). Multivariable logistic
regression analysis identified IIAT as an independent predictor of in-hospital death (adjusted odds ratio 5.28;
95% confidence interval 2.72–10.22; p= 0.012). Male gender, increasing Acute Physiology and Chronic Health
Evaluation (APACHE) II scores, greater age, and the presence of shock also predicted death.
Conclusions: Microbiologic categorization of patients with RFP suggests that antibiotic-resistant pathogens and
viruses are associated with the highest mortality rates. Vasopressor-requiring shock was common regardless of
the microbiologic categorization of RFP. Future development and use of rapid diagnostics and novel thera-
peutics targeting specific RFP pathogens may allow more timely administration of appropriate antimicrobial
therapy and enhance antibiotic stewardship practices.
Keywords: outcomes; pneumonia; respiratory failure
Pneumonia is the second most common diagnosis amongpatients requiring hospitalization and accounts for about
2.8% of all hospital stays [1]. Similarly, respiratory failure is
one of the most common medical conditions in hospitalized
patients, with increasing growth in prevalence over the past
decade [1,2]. Therefore, it is not surprising that respiratory
failure and pneumonia (RFP) often occur together, with either
pneumonia precipitating respiratory failure or complicating the
occurrence of respiratory failure from other causes.
There are limited data on the types of pneumonia, patho-
gen distribution, and clinical outcomes in patients with re-
spiratory failure. Most studies of pneumonia in critically ill
patients have focused on a specific type, such as community-
acquired pneumonia (CAP) or ventilator-associated pneu-
monia (VAP) [3–9]. The impact of initial empiric therapy on
the outcomes of patients with RFP, segregated according
to the pathogens associated with the pneumonia, also is not
well described. Moreover, the most recent guidelines from
the Infectious Diseases Society of America and the Ameri-
can Thoracic Society recommend avoidance of the term
‘‘healthcare-associated pneumonia’’ (HCAP), adding poten-
tial confusion in terms of how patients coming from the
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community with healthcare-associated risk factors should
be treated empirically [10,11]. Therefore, we performed a
prospective observational study to better understand the oc-
currence of RFP, regardless of pneumonia type (community
acquired, hospital acquired, ventilator associated), at our
institution in order to describe the etiologic agents associated
with pneumonia and their relation to clinical outcomes.
Patients and Methods
Study population and data source
The study was conducted in the two medical intensive care
units (ICUs) (34 beds) at Barnes-Jewish Hospital, an aca-
demic referral center of 1,300 beds. The medical ICUs are
geographically co-located closed units with shared physician,
nursing, pharmacist, and respiratory therapist staffs. This
investigation was approved by the Washington University
School of Medicine Human Studies Committee, and the need
for informed consent was waived (IRB No. 201509075). All
mechanically ventilated patients ( January 2016–December
2016) with pneumonia were eligible for inclusion. All me-
chanically ventilated patients were assessed daily (weekdays)
for possible study finclusion and data were collected pro-
spectively from the hospital’s electronic health record system
and from treating physicians and pharmacists.
Study outcomes/objectives
The primary objective of this study was to categorize RFP
according to one of four microbiologic categories: pathogen
negative, antibiotic susceptible, antibiotic resistant, and viral.
The primary outcomes assessed were hospital mortality rate
and inappropriate initial antibiotic therapy (IIAT) for non-
viral pathogens. Secondary outcomes were hospital length of
stay (LOS), duration of mechanical ventilation, occurrence of
a secondary pneumonia, and 90-day readmission.
Definitions and study design
Adult patients (age >18 y) were identified prospectively as
having pneumonia in accordance with the American Thor-
acic Society’s position statement on nosocomial pneumonia
[12]. The criteria were the presence of a new or progres-
sive radiographic infiltrate and at least two of the following
clinical features: Fever >38C, leukocytosis (>10· 109 cells/L),
leukopenia (£4 · 109 cells/L), or purulent secretions. The
presence of a new or progressive radiographic infiltrate was
based on the interpretation of the chest radiographs by board-
certified radiologists blinded to the study. All patient records
were reviewed by at least one of the investigators to confirm
the radiographic findings and to identify patients meeting the
case definition for pneumonia. Patients were classified as
having CAP if they met the pneumonia criteria within 24 h of
arrival at the hospital, whereas patients meeting the pneu-
monia criteria more than 24 h after hospital admission were
classified as having hospital-acquired pneumonia (HAP).
Patients were classified as having VAP if they met the
pneumonia criteria more than 24 h after the start of me-
chanical ventilation.
For purposes of this investigation, antibiotic-susceptible
RFP was determined according to ceftriaxone susceptibility,
as ceftriaxone represents the antimicrobial agent most fre-
quently recommended for hospitalized U.S. patients with
pneumonia coming from the community setting [13]. Septic
shock was defined as the need for vasopressors (norepineph-
rine, dopamine, vasopressin, epinephrine, phenylephrine). A
secondary pneumonia was defined as a distinct clinical epi-
sode meeting the pneumonia definition occurring >48 h after
completion of a course of appropriate antimicrobial therapy
for the initial episode of pneumonia. Antimicrobial treatment
was classified as IIAT if the initial regimen had no in vitro
activity against the isolated bacterial or fungal pathogen.
Immunosuppression was defined as the acquired immu-
nodeficiency syndrome, solid organ or bone marrow trans-
plant, hematologic malignancies, solid-tumor cancers treated
with chemotherapy or radiation, long-term corticosteroids
(>10 mg/d), and other immunosuppressive drugs (e.g., bio-
logics for rheumatologic disorders). Multidrug-resistant
(MDR) pathogens had to demonstrate resistance in vitro to at
least one agent from three distinct classes of antimicrobials
that normally would have activity against that bacterium [14].
Antimicrobial monitoring
From January 2002 through the present, Barnes-Jewish
Hospital utilized an antibiotic control program to help guide
antimicrobial therapy for bacterial infections. During this
time, the use of azithromycin, ceftriaxone, cefepime, genta-
micin, and vancomycin was unrestricted. However, initiation
of intravenous ciprofloxacin, imipenem, meropenem, piper-
acillin/tazobactam, ceftolozone/tazobactam, ceftazidime/
avibactam, linezolid, or ceftaroline required authorization
from either a clinical pharmacist or an infectious diseases
physician. Each ICU had a clinical pharmacist who reviewed
all antibiotic orders to ensure that dosing and interval of
administration were adequate for individual patients based on
body size, renal function, and resuscitation status.
The initial antibiotic doses employed for the treatment of
bacterial pneumonia were as follows: azithromycin 500 mg
once daily; ceftriaxone 1–2 g daily; cefepime 1–2 g q eight h;
piperacillin–tazobactam, 4.5 g q six h; imipenem 0.5 g q six h;
meropenem, 1–2 g q eight h; ceftolozone/tazobactam 1.5 g q
eight h; ceftazidime/avibactam, 2.5 g q eight h; ciprofloxacin,
400 mg q 8 h; levofloxacin 750 mg once daily; vancomycin,
15 mg/kg q 12 h; linezolid 600 mg q 12 h; and ceftaroline
600 mg q eight h. Subsequent dose and frequency were ad-
justed for decreased renal function, where appropriate.
Antimicrobial susceptibility testing
The microbiology laboratory performed antimicrobial
susceptibility of the bacterial isolates using the disk diffusion
method according to guidelines and breakpoints established
by the Clinical Laboratory and Standards Institute and pub-
lished during the inclusive years of the study [15]. All clas-
sifications of antibiotic resistance were based on in vitro
susceptibility testing using these established breakpoints.
Viral pathogens were identified using the FilmArray Re-
spiratory Panel (bioMe`rieux, Durham, NC).
Statistical analyses
The sample size was determined by the number of patients
with RFP admitted to the medical ICUs during the study
period. Continuous variables were expressed as means and
standard deviations (SDs) or medians and interquartile ranges















































(IQRs) when appropriate. The Student t test and one-way
analysis of variance (ANOVA) were used to analyze nor-
mally distributed continuous variables, whereas the Mann–
Whitney U and Kruskal–Wallis tests were used to analyze
non-normally distributed continuous variables. Categorical
data are reported as frequency distributions and were ana-
lyzed using the w2 test. We performed univariable and step-
wise backward automatic elimination multivariable logistic
regression analyses to identify the variables associated with
IIAT and death. All variables that reached a significance
threshold of £0.2 in univariable analyses were entered in the
multivariable model. We performed diagnostics for co-
linearity and tested for interactions. Goodness of fit was es-
timated using the Hosmer–Lemeshow c-statistic. P values
<0.05 were considered statistically significant, and all tests
were two-tailed. All analyses were done using SPSS Statistics
21 (IBM SPSS Statistics, Armonk, NY).
Results
Three hundred sixty-four consecutive patients with RFP
were identified. The majority were white men admitted from
home or transferred from an outside hospital, with 10% of the
patients residing in a nursing home or rehabilitation facility
before admission (Table 1). There were 237 (65.1%) patients
admitted from the community (mortality rate 30.0%), 98
(26.9%) with hospital-acquired pneumonia (mortality rate
50.0%), and 29 (8.0%) with VAP (mortality rate 44.8%)













Age 58.2 – 16.0 58.7 – 14.2 59.0 – 15.9 56.0 – 15.1 0.600
Male 31 (49.2) 63 (60.6) 68 (57.6) 41 (51.9) 0.437
Race
African American 27 (42.9) 27 (26.0) 42 (35.6) 21 (26.6) 0.075
Caucasian 36 (57.1) 73 (70.2) 75 (63.6) 57 (72.2) 0.198
Other 0 4 ( 3.8) 1 ( 0.8) 1 ( 0.8) 0.196
Location prior to admission
Home 25 (39.7) 23 (22.1) 46 (39.0) 20 (25.3) 0.014
Nursing facility 12 (19.04) 17 (16.3) 8 ( 6.8) 4 ( 5.1) 0.008
Outside hospital transfer 9 (14.3) 29 (27.9) 35 (29.7) 23 (29.1) 0.120
Lower level of care/lateral ICU 17 (27.0) 35 (33.7) 29 (24.5) 32 (40.5) 0.093
Medical history
Congestive heart failure 13 (20.6) 8 ( 7.7) 15 (12.7) 11 (13.9) 0.115
Chronic obstructive lung disease 20 (31.7) 29 (27.9) 22 (18.6) 22 (27.9) 0.191
Interstitial lung disease 0 5 ( 4.8) 4 ( 3.4) 5 ( 6.3) 0.244
Diabetes mellitus 24 (38.1) 24 (23.1) 27 (22.9) 27 (34.2) 0.059
End-stage renal disease 3 ( 4.8) 12 (11.5) 7 ( 5.9) 6 ( 7.6) 0.328
Cirrhosis 1 ( 1.6) 10 ( 9.6) 8 ( 6.8) 6 ( 7.6) 0.257
Cystic fibrosis 0 4 ( 3.9) 1 ( 0.8) 0 0.075
Bronchiectasis 1 ( 1.6) 2 ( 1.9) 0 0 0.305
Malignancy 27 (42.9) 34 (32.7) 40 (33.9) 31 (39.2) 0.503
Stem cell transplant 2 ( 3.2) 10 ( 9.6) 6 ( 5.1) 16 (20.3) <0.001
Solid organ transplant 2 ( 3.2) 10 ( 9.6) 3 ( 2.5) 4 ( 5.1) 0.098
Charlson Score 3 [ 2, 6] 3 [ 1.3, 5] 2 [ 1, 4] 3 [ 1, 5] 0.441
APACHE II 22 [19, 28] 25 [21.3, 31] 24 [19, 28.5] 23 [18, 27] 0.154
CPIS Score 9 [ 7, 10] 9 [ 7, 10] 7 [ 6, 9] 6 [ 5, 7] <0.001
Prior hospitalization (90 d) 37 (58.7) 71 (68.3) 64 (54.2) 50 (63.3) 0.193
Antibiotics within 30 days 25 (39.7) 74 (71.2) 70 (59.3) 55 (69.6) <0.001
Tracheostomy on admission 6 ( 9.5) 16 (15.4) 2 ( 1.7) 1 ( 1.3) <0.001
Mechanical ventilation (90 d) 10 (15.9) 21 (20.2) 13 (11.0) 5 ( 6.3) 0.003
Immune status
Steroids 6 ( 9.5) 39 (37.5) 20 (16.9) 22 (27.9) <0.001
Other Immunosuppressant 3 ( 4.8) 21 (20.2) 13 (11.0) 16 (20.3) 0.013
Chemotherapy (90 d) 19 (30.2) 21 (20.2) 17 (14.4) 18 (22.8) 0.154
Radiation (90 d) 6 ( 9.5) 4 ( 3.8) 2 ( 1.7) 8 (10.1) 0.078
HIV 6 ( 9.5) 3 ( 2.9) 5 ( 4.2) 3 ( 3.8) 0.234
Prior pneumonia classification
Hospital acquired 13 (20.6) 25 (24.0) 35 (29.7) 25 (31.6) 0.384
Ventilator associated 3 ( 4.8) 22 (21.2) 2 ( 1.7) 2 ( 2.5) <0.001
Community acquired 47 (74.6) 57 (54.8) 81 (68.6) 52 (65.8) 0.052
Values are expressed as medians [interquartile range], means (+ SD), or number (percent). Singificant differences are in boldface type.
APACHE =Acute Physiology and Chronic Health Evaluation; CPIS=Clinical Pulmonary Infection Score; ICU = intensive care unit;
HIV = human immunodeficiency virus.















































(p = 0.002 for mortality rate comparison). Among patients
admitted from the community, the risk factors for infection
with antibiotic-resistant pathogens were immunosuppression
(16.0%), prior hospitalization (within 90 d) (55.7%), prior
intravenous antibiotics (within 30 d) (51.5%), and admis-
sion from a nursing care facility (14.8%). Sixty-three (17.3%)
patients were classified as having antibiotic-susceptible pneu-
monia, 104 (28.6%) had antibiotic-resistant organisms, 118
(32.4%) were pathogen negative, and 79 (21.7%) were in-
fected with viruses. The pathogens identified are shown in
Table 2, and the culture specimens obtained are shown
in Supplementary Table 1. Staphylococcus aureus (15.1%;
methicillin resistant 41.8%) was the most common pathogen
associated with RFP followed by Pseudomonas aeruginosa
(6.3%), rhinovirus (5.6%), and influenza A (3.3%). The En-
terobacteriaceae as a class accounted for 11.0% of RFP cases.
Inappropriate antimicrobial therapy was identified in
3.2% of patients with antibiotic-susceptible infections, 21.2%
with antibiotic-resistant infections, and 0.8% of pathogen-
negative infections (one patient who did not have an anti-
biotic order entered) (p < 0.001) (Table 3). Patients with
antibiotic-resistant infections were statistically more likely
to receive IIAT than were those with antibiotic-susceptible
infections (p < 0.001). The in = hospital mortality rate was




(n= 104) Viral (n = 79)d
Staphylococcus aureus 32 (50.8) Staphylococcus aureus 28 (26.9) Rhinovirus/enterovirus 20 (25.3)
Streptococcus pneumoniae 9 (14.3) Pseudomonas aeruginosa 23 (22.1) Influenza A 12 (15.2)
Klebsiella pneumoniae 8 (12.7) Stenotrophomonas
maltophilia
10 ( 9.6) Respiratory syncytial
virus
11 (13.9)
Haemophilus influenzae 4 ( 6.3) Enterobacter spp. 10 ( 9.6) Coronavirus 11(13.9)
Escherichia coli 3 ( 4.8) Aspergillus fumigatus 7 ( 6.7) Metapneumovirus 8 (10.1)
Moraxella catarrhalis 3 ( 4.8) Escherichia coli 5 ( 4.8) Parainfluenza virus 7 ( 8.9)
Proteus spp. 3 ( 4.8) Klebsiella pneumoniae 3 ( 2.9) Adenovirus 6 ( 7.6)
Other Streptococcus spp. 3 ( 4.8) Acinetobacter baumannii 3 ( 2.9) Cytomegalovirus 5 ( 6.3)
Morganella morganii 2 ( 3.2) Achromobacter spp. 3 ( 2.9) Influenza B 1 ( 1.3)
Citrobacter koseri 1 ( 1.6) Providencia spp. 3 ( 2.9)
Providencia stuartii 1 ( 1.6) Legionella pneumophila 3 ( 2.9)
Multiple pathogensb 11 (17.5) Enterococcus spp.c 2 ( 1.9)
Pneumocystis jiroveci 2 ( 1.9)
Histoplasma capsulatum 2 ( 1.9)
Serratia marcescens 1 ( 1.0)
Mycobacterium tuberculosis 1 ( 1.0)
Streptomyces sp. 1 ( 1.0)
Trichosporium 1 ( 1.0)
Blastomyces dermatitidis 1 ( 1.0)
Chryseobacterium 1 ( 1.0)
Paecilomyces 1 ( 1.0)
Multiple pathogensb 15 (14.4)
aValues are expressed as number (percent).
bIncluding co-infection with viral pathogens
cAssociated with concomitant isolation from pulmonary source and blood.
dRepresents patients with only viruses identified as causative pathogen for pneumonia.
Table 3. Clinical Outcomes for Mechanically Ventilated Patients









(n = 118) Viral (n = 79) p
Deaths 17 (27.0) 50 (48.1) 37 (31.4) 29 (36.7) 0.020
Length of stay 15 [ 8, 25] 18.5 [11, 30.8] 11 [ 6.50, 20.5] 18 [ 9.5, 28.75] 0.002
Intensive care unit
length of stay
8 [ 4, 16] 9 [ 6, 17] 6 [ 4, 12] 8 [ 4, 18.25] 0.025
Ventilator d 4 [ 3, 11] 7.5 [ 4, 15] 4 [ 2, 8.5] 6 [ 2, 13] 0.003
Antibiotic d 10 [ 7, 14] 11 [ 7, 14] 7 [ 5, 9.3] 7 [ 4, 11] <0.001
Vasopressor d 3 [ 2, 5] 4 [ 2, 8] 3 [ 2, 4] 4 [ 2, 11.5] 0.014
Inappropriate initial
antimicrobial therapy
2 ( 3.2) 22 (21.2) 1 ( 0.8) 0 ( 0) 0.000
Second pneumonia 12 (19.0) 12 (11.5) 9 ( 7.6) 9 (11.4) 0.154
90-d readmission 15 (23.8) 17 (16.3) 25 (21.1) 11 (13.9) 0.559
Values are expressed as medians [interquartile range] or number (percent).















































greatest for patients with an antibiotic-resistant infection
(48.1%), followed by viral (36.7%), pathogen-negative (31.4%),
and antibiotic-susceptible (27.0%) infections. The hospital
LOS was significantly longer for patients with antibiotic-
resistant and viral pneumonias. Antibiotic duration of ther-
apy was significantly longer for pneumonia attributed to
antibiotic-resistant and antibiotic-susceptible pathogens.
We found that 53 of the 79 patients (67.1%) with RFP
attributed to a viral infection, with only 1 (1.3%) of these
individuals having microbiologic evidence of a coexistent
non-pulmonary bacterial infection, suffered shock necessi-
tating vasopressor therapy. This was similar to the rate of
shock seen in patients with antibiotic-susceptible infections
(61.9%), antibiotic-resistant infections (72.1%), and pathogen-
negative infections (68.6%) (p= 0.585 for the group compar-
ison). However, patients with viral pneumonia and those with
antibiotic-resistant infections had greater durations of vaso-
pressor administration (Table 3).
The univariable analysis for in-hospital deaths is shown in
Supplementary Table 2. Other outcomes according to hos-
pital survivorship are shown in Supplementary Table 3.
Nonsurvivors spent more time on mechanical ventilation,
required more days of vasopressor therapy, and were sig-
nificantly more likely to receive IIAT. The results of the
multivariable analysis are shown in Table 4. Inappropriate
initial antibiotic therapy was identified as an independent
predictor of in-hospital death (adjusted odds ratio [AOR]
5.28; 95% confidence interval [CI] 2.72–10.22; p = 0.012).
Male gender, increasing age, higher APACHE II scores, and
the presence of shock also predicted death. A second multi-
variable analysis was conducted with IIAT as the dependent
outcome variable. In this analysis, VAP (AOR 4.22; 95% CI
2.25–7.92; p = 0.022), shock (AOR 14.03; 95% CI 4.88–
40.33; p= 0.012), and prior mechanical ventilation (90 days)
(AOR 2.00; 95% CI 1.44–2.77; p = 0.034) predicted IIAT
(Hosmer-Lemeshow goodness-of-fit score 0.871).
Discussion
Microbiologic categorization of patients with RFP sug-
gests that antibiotic-resistant pathogens and viruses are
associated with worse outcomes than are seen in patients
with antibiotic-susceptible and pathogen-negative pneumo-
nia. Disease attributed to antibiotic-susceptible pathogens
and pathogen-negative cases had lower mortality rates and
significantly lower rates of IIAT than patients with antibiotic-
resistant infections despite similar severity of illness. In-
appropriate initial antibiotic therapy and shock were the only
potentially modifiable risk factors we identified that were
associated with death. Interestingly, less than 10% of our
entire cohort had VAP, with the majority of the RFP patients
who subsequently developed respiratory failure being clas-
sified as either CAP or HAP. Nevertheless, the presence
of VAP was a predictor of IIAT. We also found that most
patients with viral pneumonia suffered shock and that the
appearance of shock was similar to that observed in the other
pathogen-based groupings of pneumonia. Interestingly, al-
most one quarter of patients with RFP classified as CAP
had infection with antibiotic-resistant pathogens, implying a
potential flaw with current guidelines suggesting that such
patients be treated automatically with ceftriaxone or an
equivalent agent [10].
Our data highlight the complexity of RFP because of the
variability in the types of patients who develop this infection,
as well as the variability in the associated pathogens. Tradi-
tional approaches for selecting empiric therapy for pneu-
monia have focused on the bacterial organisms associated
with this infection [10]. Most authors suggest that the pres-
ence of specific risk factors predisposing to infection with
potentially antibiotic-resistant bacteria, such as methicillin-
resistant S. aureus (MRSA) and Pseudomonas aeruginosa,
should prompt initial broader-spectrum empiric coverage for
these pathogens [10,16]. However, this approach of ‘‘clinical
reasoning,’’ even when supplemented by institution-specific
algorithms developed for the prediction of infection with
antibiotic-resistant bacteria, is of limited clinical utility [17].
This inaccuracy in clinical decision-making often leads to
overtreatment with empiric broad-spectrum antibiotics but
also the administration of IIAT [17,18]. The recent recom-
mendation to eliminate the use of the term ‘‘HCAP’’ is
in large part a response to the increasing use of empiric broad-
spectrum antibiotics in patients with community-onset
pneumonia [10,19]. However, minimizing the administration
of IIAT is also an important determinant of outcome that
clinicians should take into account when deciding which
pathogens to cover with the initial empiric antimicrobial
regimen [8].
Rapid microbiologic diagnostics represents a strategy that
may improve the way antibiotic therapy is directed to patients
with RFP, as well as how antibiotic therapy is provided to
patients with pneumonia not complicated by respiratory
failure. Such technologies have the capability of providing
pathogen identification and true antibiotic susceptibility
within six h from the time a specimen is logged in to the
microbiology laboratory [20]. This could minimize the time
that patients are exposed to IIAT. Moreover, the availability
of rapid true susceptibility data also can be used to de-
escalate empiric broad-spectrum antibiotic therapy at an
earlier point in time. A recent meta-analysis of rapid micro-
biologic diagnostic assays suggests that when the clinical
use of such technology is incorporated into antimicrobial
stewardship programs,in- hospital mortality rates can be
reduced [21].
Table 4. Multivariable Logistic Regression
Analysis with Hospital Morality
Rate as the Dependent Variable
Variable aOR 95% CI p
Age (one-point increments) 1.05 1.03– 1.07 0.032
Male gender 3.67 2.02– 6.67 0.030
APACHE II score
(one-point increments)
1.14 1.09– 1.19 0.003




Removed from model for non-significance: Caucasian race, African-
American race, congestive heart failure, interstitial lung disease,
cirrhosis, underlying malignancy, stem cell transplant, Charlson
score, prior hospitalization, prior antibiotic exposure, hospital-
acquired pneumonia, community-acquired pneumonia, admission
from home.
APACHE =Acute Physiology and Chronic Health Evaluation;
aOR = adjusted odds ratio; CI = confidence interval.
Hosmer-Lemeshow goodness-of-fit = 0.547.















































Several limitations of our study should be recognized.
First, it was performed at a single center and may not reflect
the types of patients or pathogens seen at other hospitals.
Barnes-Jewish Hospital has a regional referral pattern that
includes community hospitals, long-term acute-care hospi-
tals, nursing homes, and chronic wound, dialysis, and infu-
sion clinics. Patients transferred from these settings are more
likely to be infected with antibiotic-resistant bacteria and
non-bacterial pathogens. This may explain the relatively high
rates of infection with antibiotic-resistant gram-negative
bacteria and MRSA in our cohort. Second, we had a relatively
low rate of IIAT, which may reflect the long history of an-
timicrobial stewardship being practiced in these closed ICUs
[22,23]. Third, the rate of observed VAP was low in our
population. This may be a reflection of referral patterns to our
hospital accounting for a much larger percentage of patients
with CAP and HAP. It also may represent the presence
of ICU protocols aimed at minimizing the occurrence of
VAP [24,25]. Fourth, we cannot exclude the possibility that
patients with pathogen-negative and viral pneumonia had
a concomitant bacterial infection in some instances that
was not detected by our conventional microbiology tech-
niques [26]. Fifth, we included patients who were immuno-
suppressed in order to have a more representative picture of
the types of patients and pathogens presenting to the ICU with
RFP. Finally, we excluded antiviral therapies when deter-
mining the presence of IIAT given the limitations of available
anti-viral drugs and their influence on patient outcomes.
In conclusion, we found that patients with RFP represent a
heterogeneous group composed primarily of patients with
CAP and HAP. Although the number of patients receiving
IIAT was small, most of the IIAT was secondary to infection
with antibiotic-resistant bacteria and non-bacterial patho-
gens. These findings have important implications for asses-
sing and comparing the outcomes of patients with pneumonia
from different institutions. Intuitively, it would not be fair to
compare an ICU caring disproportionately for patients with
antibiotic-resistant pathogens with one where patients with
antibiotic-susceptible infections predominate. Moreover, our
data suggest that advances in the development and utilization
of rapid diagnostics targeting antibiotic-resistant bacterial,
fungi, and viruses may help in directing the initial antimi-
crobial therapy of patients with RFP. Future development
and clinical use of rapid diagnostics and novel therapeutics
targeting specific RFP pathogens should allow more timely
administration of appropriate antimicrobial therapies and
enhanced antibiotic stewardship efforts.
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